Moxonidine Effects on Neuropeptide Y

Phase 4

Completed

• Conditions: Obesity; Hypertension
• Interventions: Drug: Moxonidine

• Registration Number: NCT05147753
• Lead Sponsor: Aristotle University Of Thessaloniki

Brief Summary

Treatment with monotherapy of moxonidine 0.6 mg daily in treatment-naïve subjects with mild or moderate hypertension

Detailed Description

Treatment with 0.6 mg moxonidine daily in treatment-naïve subjects with mild or moderate hypertension according to guidelines (Stage 1: Systolic Blood Pressure =140-159 mmHg, Diastolic Blood Pressure =90-99 mmHg, and Stage 2: systolic blood pressure=160-179 mmHg, diastolic blood pressure=100-109 mmHg) that require monotherapy and reevaluation after 12 weeks

Study Timeline

• Study Start: 2010-01-11
• Primary Completion: 2014-06-30
• Study Completion: 2014-06-30
• Status Verified: 2021-11
• Study First Submitted: 2021-11-18
• Study First Submitted QC: 2021-11-24
• Last Update Submitted: 2021-11-24
• Study First Posted: 2021-12-07
• Last Update Posted: 2021-12-07

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 90

Inclusion Criteria

• treatment-naïve subjects with mild or moderate hypertension according to Joint National Committee 7 and European Society Hypertension / European Society Cardiology 2008 (Stage 1: Systolic Blood Pressure =140-159 mmHg, Diastolic Blood Pressure =90-99 mmHg, and Stage 2: Systolic=160-179 mmHg, Diastolic=100-109 mmHg) that require monotherapy

Exclusion Criteria

• age beyond 25-75 years,
• not taking currently anti-hypertensive medication
• not taking anti-diabetic or lipid lowering medication and other diseases or conditions that may influence blood pressure, heart rate and catecholamines' and Neuropeptide Y levels, including anemia, fever, stage III hypertension, coronary artery disease, recent (less than 6 months) myocardial infraction or stroke, heart failure, secondary hypertension, diabetes mellitus, abnormal thyroid status or other obesity-related endocrinopathies, pregnancy, kidney failure, alcohol abuse, malignancies, depression or other psychiatric illnesses, such as schizophrenia,

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Group	Moxonidine	0.6 mg moxonidine daily

Primary Outcome Measures

Name	Time	Method
serum Neuropeptide Y levels	12 weeks	ELISA
systolic blood pressure	12 weeks	mmHg
diastolic blood pressure	12 weeks	mmHg

Secondary Outcome Measures

Name	Time	Method
Weight	12 weeks	kg
LDL Cholesterol	12 weeks	mg/dl
HDL Cholesterol	12 weeks	mg/dl
Serum triglycerides	12 weeks	mg/dl
Body Mass Index	12 weeks	kg/m2
Total Cholesterol	12 weeks	mg/dl